What's Going On With Pfizer On Thursday? Pharma Giant's Shares Tick Lower
What's Going On With Pfizer On Thursday? Pharma Giant's Shares Tick Lower
Pfizer Inc. (NYSE:PFE) shares are ticking lower after the company disclosed disappointing results from its Phase 3 CIFFREO study, evaluating the investigational gene therapy for Duchenne muscular dystrophy (DMD) in young boys.
輝瑞公司（NYSE:PFE）公佈了CIFFREO第三期研究的令人失望的結果後，其股價有所下跌。該研究評估了用於年輕男孩的Duchenne肌肉萎縮症（DMD）的研究性基因治療的有效性。
The study did not achieve its primary endpoint of improving motor function in patients aged 4 to 7 years.
該研究未能實現改善4至7歲患者運動功能的主要終點。
The multinational, placebo-controlled trial assessed the efficacy of the gene therapy using the North Star Ambulatory Assessment (NSAA) over one year.
這項跨國安慰劑對照試驗評估了一年內使用北極星步行評估（NSAA）的基因治療的療效。
Also Read: Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer
此外，輝瑞還強調，在一種罕見的晚期肺癌形式中使用的癌症藥物的數據已有空前的5年。
Despite high hopes, both the primary and key secondary outcomes, such as 10-meter run/walk velocity, showed no significant improvement over placebo.
儘管期望很高，但主要和關鍵的次要結果，如10米跑/行走速度，與安慰劑組相比沒有顯着改善。
The trial aimed to introduce a shortened version of the human dystrophin gene, which is absent in DMD patients, into their cells, reported Reuters.
這項試驗旨在將缺失在DMD患者中的人類肌萎縮蛋白基因的縮短版本引入到他們的細胞中（Reuters報道）。
Duchenne muscular dystrophy is a devastating genetic condition causing progressive muscle degeneration and weakness, primarily affecting boys. It manifests in early childhood and leads to severe physical impairments and life expectancy reduction.
Duchenne肌肉萎縮症是一種毀滅性的遺傳病，主要影響男孩，會引發漸進性肌肉退化和肌無力，最終導致嚴重的身體殘障和壽命縮短。該病在幼兒期表現出來。
Pfizer remains committed to the ongoing monitoring of all participants and is currently reassessing the next steps for its DMD program.
輝瑞仍致力於對所有參與者的持續監測，並正在重新評估其DMD計劃的下一步計劃。
This setback follows a recent serious adverse event that paused dosing in another related trial, underscoring the challenges in developing treatments for this severe genetic disorder.
此次挫折緊隨另一項相關試驗暫停服藥的嚴重不良事件之後，凸顯了開發治療這種嚴重遺傳性疾病面臨的挑戰。
This trial outcome adds to Pfizer's challenges, as the company seeks new revenue streams following the decline in sales from its COVID-19 products.
這項試驗結果增加了輝瑞的挑戰，因爲該公司正在尋求新的營業收入來源，以彌補其COVID-19產品銷售下降的損失。
The failure of this therapy, intended as a one-time treatment, may impact Pfizer's financial forecasts and ongoing research priorities.
作爲一次一次性治療的治療失敗，可能會影響輝瑞的財務預測和持續的研究重心。
Price Action: PFE shares are trading lower by 0.43% at $27.54 in premarket at the last check Thursday.
股票價格：最後檢查的週四，在盤前交易中，PFE股價下跌0.43%，至27.54美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明: 此內容部分使用人工智能工具生成，並由Benzinga編輯審查和發佈。
Read Next: Pfizer Initiates Multi-Year Cost Reduction Plan Targeting $1.5B Savings By 2027
閱讀下一篇：輝瑞啓動爲期數年的成本削減計劃，目標是在2027年前實現15億美元的節約。
Image: Shutterstock
圖片：shutterstock
譯文內容由第三人軟體翻譯。